Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01904643 · ClinicalTrials.gov registry record · Phase 1
Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT01904643: Clinical Trial Phase 1 study, sponsored by Stanford University.
NCT01904643 is a Phase 1 study that was terminated before completion, run by Stanford University. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01904643, a Phase 1 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and the best dose of lenalidomide when given together with combination chemotherapy in treating patients with relapsed or refractory acute myeloid leukemia. Lenalidomide may stop the growth of acute myeloid leukemia by blocking blood flow to the cancer. Drugs used in chemotherapy, such as mitoxantrone hydrochloride, etoposide, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide and combination chemotherapy may be an effective treatment for acute myeloid leukemia.
Interventions
- DRUG lenalidomide
- DRUG etoposide
- DRUG cytarabine
- DRUG mitoxantrone hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-07-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01904643
The ClinicalTrials.gov registry entry for NCT01904643 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which lenalidomide is the first listed.
NCT01904643 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01904643 about?
NCT01904643 is a clinical study titled "Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia". This phase I trial studies the side effects and the best dose of lenalidomide when given together with combination chemotherapy in treating patients with relapsed or refractory acute myeloid leukemia. Lenalidomide may stop the growth of acute myeloid leukemia by blocking blood flow to the cancer. Dr...
What is the current status of trial NCT01904643?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2014-02. Estimated completion is 2015-07-18.
What interventions are being tested in trial NCT01904643?
The interventions under investigation include: lenalidomide (DRUG), etoposide (DRUG), cytarabine (DRUG), mitoxantrone hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01904643?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.